Centiva Capital LP Has $384,000 Position in Bausch Health Companies Inc. (NYSE:BHC)

Centiva Capital LP lessened its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 59.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 47,607 shares of the company’s stock after selling 68,984 shares during the quarter. Centiva Capital LP’s holdings in Bausch Health Companies were worth $384,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Tobam increased its stake in shares of Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after buying an additional 1,422 shares during the period. Wells Fargo & Company MN raised its holdings in Bausch Health Companies by 7.9% in the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company’s stock worth $209,000 after purchasing an additional 1,896 shares during the period. American Century Companies Inc. raised its holdings in Bausch Health Companies by 10.6% in the fourth quarter. American Century Companies Inc. now owns 27,236 shares of the company’s stock worth $220,000 after purchasing an additional 2,600 shares during the period. Blair William & Co. IL raised its holdings in Bausch Health Companies by 3.2% in the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company’s stock worth $683,000 after purchasing an additional 2,622 shares during the period. Finally, Sanders Morris Harris LLC raised its holdings in shares of Bausch Health Companies by 16.0% during the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock worth $234,000 after acquiring an additional 4,000 shares during the period. Institutional investors and hedge funds own 78.65% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Royal Bank of Canada raised their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. StockNews.com downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.42.

Bausch Health Companies Stock Performance

NYSE BHC opened at $4.55 on Monday. The firm has a 50-day moving average of $5.79 and a 200-day moving average of $7.09. The stock has a market cap of $1.65 billion, a PE ratio of -37.91, a P/E/G ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $9.85.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. As a group, analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.